/BICTF

BICTF Stock - Biocure Technology Inc.

Q: What is the analyst price target for BICTF?

Analyst price target information is not currently available for BICTF.

Q: What is BICTF's market cap?

Market capitalization information is not currently available for BICTF.

Healthcare|Biotechnology|OTC

$0.01+0.00%

+$0.00 (+0.00%) • Dec 19

GoAI Score

Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.

HOLD

Medium Confidence

Momentum

Momentum Score

Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.

Sentiment

Sentiment Score

Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).

Risk Score

Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.

Price Target

Average analyst price target from the last quarter. Shows expected upside/downside from current price.

+10.0%upside

Target: $0.01

AI Analysis PreviewPremium

Real-time AI-powered market analysis

Precise entry/exit price targets

Risk assessment & position sizing

Unlock GoAI Insights for BICTF

Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.

Buy/Sell Signals

94% win rate on Alpha signals

Deep Analysis

Institutional-grade thesis

Real-Time Alerts

SMS & push notifications

Risk Scoring

Multi-factor analysis

Free 14-day trial • No credit card required

Financial Statements

Revenue & Profitability Trend

FY2020

FY2021

FY2022

FY2023

FY2024

← Swipe to see more →

Revenue

Net Income (Profit)

Net Loss

Key Metrics

Market CapN/A

P/E RatioN/A

Beta4.23

52W High$0.63

52W Low$0.00

Avg VolumeN/A

Income Statement (Fiscal Year)

Metric	FY2024	FY2023	FY2022	FY2021	FY2020
Revenue	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	$-43,091
Gross Margin	N/A	N/A	N/A	N/A	N/A
Operating Income	$-318,236	$-1,052,000	$-674,000	$-1,734,699	$-3,005,000
Net Income	$-262,471	$-1,814,000	$-1,450,000	$-1,128,000	$-2,946,000
Net Margin	N/A	N/A	N/A	N/A	N/A
EPS	$-0.03	$-0.01	$-0.00	$-0.01	$-0.03

Company Overview

Biocure Technology Inc., together with its subsidiary, engages in developing and commercializing biopharmaceutical technologies for use in recombinant and ranibizumab. The company is developing Interferons-ß for the treatment of multiple sclerosis; Ranibizumab, a monoclonal antibody fragment for the treatment of macular degeneration, as well as to treat a type of eye problem known as macular edema; and Filgrastim to treat neutropenia, a lack of white blood cells caused by cancer, bone marrow transplant, chemotherapy, or by other conditions. It also engages in the research and development of CAR T Cell therapy that identifies and destroys cancer cells; a foot and mouth disease vaccine; and hair growth products. The company was founded in 2005 and is headquartered in Vancouver, Canada.

Visit Website